Abstract
Background: Data on the safety and efficacy of coronavirus disease 2019 (COVID-19) vaccination in people with a range of primary immunodeficiencies (PIDs) are lacking because these patients were excluded from COVID-19 vaccine trials. This information may help in clinical management of this vulnerable patient group.
Objective: We assessed humoral and T-cell immune responses after 2 doses of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger RNA (mRNA) vaccines in patients with PID and functional B-cell defects.
Methods: A double-center retrospective review was performed of patients with PID who completed COVID-19 mRNA vaccination and who had humoral responses assessed through SARS-CoV-2 spike protein receptor binding domain (RBD) IgG antibody levels with reflex assessment of the antibody to block RBD binding to angiotensin-converting enzyme 2 (ACE2; hereafter referred to as ACE2 receptor blocking activity, as a surrogate test for neutralization) and T-cell response evaluated by an IFN-γ release assay. Immunization reactogenicity was also reviewed.
Results: A total of 33 patients with humoral defect were evaluated; 69.6% received BNT162b2 vaccine (Pfizer-BioNTech) and 30.3% received mRNA-1273 (Moderna). The mRNA vaccines were generally well tolerated without severe reactions. The IFN-γ release assay result was positive in 24 (77.4%) of 31 patients. Sixteen of 33 subjects had detectable RBD-specific IgG responses, but only 2 of these 16 subjects had an ACE2 receptor blocking activity level of ≥50%.
Conclusion: Vaccination of this cohort of patients with PID with COVID-19 mRNA vaccines was safe, and cellular immunity was stimulated in most subjects. However, antibody responses to the spike protein RBD were less consistent, and, when detected, were not effective at ACE2 blocking.
Keywords: ACE2 blocking antibody; Good syndrome; SARS-CoV-2; SARS-CoV-2 IFN-γ release assay; SARS-CoV-2 spike protein antibody; SARS-CoV-2 vaccination; antibody deficiency; common variable immunodeficiency; mAb; primary immunodeficiency.
【저자키워드】 SARS-CoV-2, Antibody deficiency, SARS-CoV-2 vaccination, mAb, ACE2 blocking antibody, Good syndrome, SARS-CoV-2 IFN-γ release assay, SARS-CoV-2 spike protein antibody, common variable immunodeficiency, primary immunodeficiency., 【초록키워드】 COVID-19, coronavirus disease, Coronavirus disease 2019, Efficacy, ACE2, Vaccine, BNT162b2 vaccine, coronavirus, vaccination, reactogenicity, antibody, mRNA vaccine, mRNA-1273, neutralization, Antibody Response, T-cell Response, immunodeficiency, Primary Immunodeficiency, ACE2 receptor, severe acute respiratory syndrome Coronavirus, angiotensin-converting enzyme 2, Spike protein, Receptor binding domain, mRNA vaccines, BNT162b2, Antibody responses, IgG antibody, Humoral response, cellular immunity, RBD, mRNA, immune responses, SARS-CoV-2 spike protein, Patient, Clinical management, humoral responses, respiratory, information, patients, Pfizer-BioNTech, SARS-CoV-2 vaccination, Moderna, IFN-γ, B-cell, T-cell immune response, common variable immunodeficiency, Angiotensin-converting enzyme, retrospective, dose, angiotensin, Primary immunodeficiencies, Safe, humoral, referred to, IgG responses, retrospective review, not effective, blocking antibody, COVID-19 mRNA Vaccination, Messenger RNA, acute respiratory syndrome, Reactions, acute respiratory syndrome coronavirus, acute respiratory syndrome coronavirus 2, subject, enzyme, COVID-19 vaccine trials, SARS-CoV-2 spike protein receptor binding domain, help, RBD binding, spike protein RBD, positive, blocking activity, Good, effective, PIDs, stimulated, detectable, evaluated, was performed, functional, less, subjects, the spike protein, cohort of patient, PID, RBD-specific IgG responses, were excluded, with COVID-19, 【제목키워드】 COVID-19, Vaccine, immunogenicity, Patient, B-cell, Messenger RNA, Tolerability, functional,